ResearcherFirst Affiliated Hospital Zhejiang UniversityNo recent work listed

Tingbo Liang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8555-2204. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2023: 1 paper

Papers 1

In Situ Formed ROS-Responsive Hydrogel with STING Agonist and Gemcitabine to Intensify Immunotherapy against Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1002/adhm.202203264 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Meng Wang · 1 shared paper, 2023 · strength 0.19
- Paper In Situ Formed ROS-Responsive Hydrogel with STING Agonist and Gemcitabine to Intensify Immunotherapy against Pancreatic… DOI 10.1002/adhm.202203264 ↗
Junming Huang · 1 shared paper, 2023 · strength 0.19
- Paper In Situ Formed ROS-Responsive Hydrogel with STING Agonist and Gemcitabine to Intensify Immunotherapy against Pancreatic… DOI 10.1002/adhm.202203264 ↗
Qida Hu · 1 shared paper, 2023 · strength 0.19
- Paper In Situ Formed ROS-Responsive Hydrogel with STING Agonist and Gemcitabine to Intensify Immunotherapy against Pancreatic… DOI 10.1002/adhm.202203264 ↗
Shiyi Shao · 1 shared paper, 2023 · strength 0.19
- Paper In Situ Formed ROS-Responsive Hydrogel with STING Agonist and Gemcitabine to Intensify Immunotherapy against Pancreatic… DOI 10.1002/adhm.202203264 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.